We evaluated markers of artemisinin resistance in Plasmodium falciparum isolated in Kampala in 2014. By standard in vitro assays, all isolates were highly sensitive to dihydroartemisinin (DHA). By the ring-stage survival assay, after a 6-h DHA pulse, parasitemia was undetectable in 40 of 43 cultures at 72 h. Two of 53 isolates had nonsynonymous K13-propeller gene polymorphisms but did not have the mutations associated with resistance in Asia. Thus, we did not see evidence for artemisinin resistance in Uganda.A rtemisinin-based combination therapy is now the standard for treating P. falciparum malaria. However, this regimen is threatened by resistance to artemisinins, which manifests as delayed clearance of parasitemia after therapy, in Southeast Asia (1, 2). Recently, resistance has been associated with increased parasitemia in culture, compared to that in sensitive parasites, 72 h after a 6-h pulse with dihydroartemisinin (DHA) and has been associated with polymorphisms in propeller-encoding domains of the Plasmodium falciparum kelch (K13; UniProt number PF3D7_1343700) gene (3-6). Although artemisinin resistance is evident to date only in Southeast Asia, the bulk of P. falciparum malaria occurs in sub-Saharan Africa. Clinical resistance has not been noted in Africa, as rapid parasite clearance has been the rule in many trials, including those in Uganda (7-9). In recent surveys in Uganda (10) and other locations in Africa (11-15), K13-propeller gene polymorphisms were identified, but these were not the mutations clearly associated with artemisinin resistance in Asian isolates. Results for a new correlate of artemisinin resistance, the ex vivo ring-stage survival assay (RSA) (3), have not been reported previously for P. falciparum isolates from Africa. We characterized artemisinin sensitivity by this assay and assessed K13 polymorphisms in isolates from Uganda. Parasites were collected from patients diagnosed with malaria from May to August 2014 at Mulago Hospital, Kampala. Samples were delinked from patient information, so clinical data were unavailable. After malaria diagnosis, excess blood collected in a heparinized tube as part of clinical care was promptly delivered to the laboratory. Giemsastained thin smears were made, and samples containing only P. falciparum isolates with parasitemia of Ն0.1% were placed in culture after washing of erythrocytes, as previously described (16); blood was also spotted onto filter paper. Samples with parasitemia of Ͼ1% were diluted with uninfected erythrocytes for a final parasitemia of 1%.The susceptibility of fresh isolates to DHA and chloroquine was assessed by a standard ex vivo histidine-rich protein 2-based enzyme-linked immunosorbent microplate assay, as previously described (17), except that drugs were freshly diluted from frozen stocks prior to each assay. Results from single assays were fitted to a variable-slope sigmoidal function using GraphPad Prism 6.0f to generate 50% inhibitory concentrations (IC 50 s). All data were visually assessed for parasite growth above...